ALNY Financial Facts
Unrealized (loss) gain on marketable securities: -18.33MTotal other income (expense): 2.32M
See Full Income Statement
Total liabilities and stockholders' equity: 1.38B
Additional paid-in capital: 2.57B
See Full Balance Sheet
Alnylam Pharmaceuticals, Inc. (ALNY) Earnings
|
Expand Research on ALNY
| Next EPS Date | 8/3/22 *Est. | EPS Growth Rate | +9.1% *Last Qtr. |
|---|---|---|---|
| Average EPS % Beat Rate | +5.0% | Revenue Growth Rate | +20.1% *Last Qtr. |
| Average % Move 1-Wk after EPS | -0.8% | Normal Earnings Time | Before Open |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 4/28/22 |  |
Q122 | -$1.49 | -$1.84 | +$0.35 | $213.26M | $243.02M | N/A |  | | Details |
| 2/10/22 | |
Q421 | -$1.69 | -$1.56 | -$0.13 | $258.5M | $231.44M | N/A | | | Details |
| 10/28/21 | |
Q321 | -$1.72 | -$1.57 | -$0.15 | $187.6M | $218.54M | N/A | | | Details |
| 8/3/21 | |
Q221 | -$1.30 | -$1.60 | +$0.30 | $220.1M | $193.18M | N/A | | | Details |
| 4/29/21 | |
Q121 | -$1.64 | -$1.75 | +$0.11 | $177.6M | $168.74M | N/A | | | Details |
| 2/11/21 | |
Q420 | -$1.60 | -$1.76 | +$0.16 | $163.6M | $146.07M | N/A | | | Details |
| 11/5/20 | |
Q320 | -$1.58 | -$1.66 | +$0.08 | $125.9M | $120.75M | N/A | | | Details |
| 8/6/20 | |
Q220 | -$1.67 | -$1.74 | +$0.07 | $104M | $99.48M | N/A | | | Details |
